Arcturus Selling And Marketing Expenses from 2010 to 2025
| ARCT Stock | USD 16.56 0.50 3.11% |
Selling And Marketing Expenses | First Reported 2010-12-31 | Previous Quarter 2.7 M | Current Value 2.4 M | Quarterly Volatility 160.8 K |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 530 K or Selling General Administrative of 63.8 M, as well as many indicators such as Price To Sales Ratio of 4.55, Dividend Yield of 0.0 or PTB Ratio of 2.85. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Arcturus | Selling And Marketing Expenses |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.